Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination Strategies in Pediatric Cancer Survivors
NCT04948619Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2022
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Haemophilus influenzae type b infection (Hib), Tetanus, diphtheria and 8 more (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Vaccination comparison via objective lab measurements of vaccine titers at 2 years. Started Aug 2022; status: recruiting.
02
Conditions
Haemophilus influenzae type b infection (Hib)Tetanusdiphtheriapertussispoliomyelitis
Beyond the preview
Go deeper on NCT04948619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948619.